10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

Rhea-AI Summary

10x Genomics, Inc. announces the commercial availability of the Xenium Cell Segmentation Kit and the launch of the Xenium Immuno-Oncology Panel. The company aims to enhance single cell spatial analysis with advanced AI algorithms and diverse stains, catering to researchers' needs for accurate cell segmentation and in-depth tumor microenvironment analysis.

Insights

Biotech Industry Analyst

The introduction of 10x Genomics' Xenium multi-modal cell segmentation kit and the immuno-oncology gene panel signify a strategic expansion in the company's product offerings. This move is indicative of the growing demand for precision in single-cell analysis, particularly in the field of immuno-oncology, which is a key area for the development of personalized medicine.

From a business perspective, the launch of these products may lead to increased market share for 10x Genomics in the competitive landscape of biotechnology. The company's focus on improving the accuracy of cell segmentation through machine learning models and the ability to customize gene panels, addresses a critical need for researchers. This could translate into higher sales volumes, as laboratories and research institutions seek to leverage the latest technologies for more precise data analysis.

Moreover, the compatibility of these products with both fresh frozen and FFPE tissues broadens the potential user base, which is a positive indicator for the company's revenue growth. However, the impact on the stock market will likely depend on the adoption rate of these new offerings and the company's ability to effectively manage production and distribution.

Financial Analyst

Investors will be interested in the potential revenue implications of these new product launches by 10x Genomics. The company's investment in product development, particularly in the high-growth area of immuno-oncology, could be a significant driver of future earnings.

While the initial costs associated with research and development, as well as marketing for new products, might affect short-term profitability, the long-term gains from securing a stronger position in the market could be substantial. The ability to offer a unique, application-focused panel optimized for immuno-oncology across all tissue types may create a competitive edge and justify a premium pricing strategy.

It is also important to monitor the company's operational efficiency post-launch. The management's commentary on having 'several more launches planned for Xenium this year' suggests an aggressive growth strategy, which could be a double-edged sword, potentially leading to either significant market capture or overextension of company resources.

Medical Research Analyst

The clinical implications of the Xenium cell segmentation kit and immuno-oncology panel are substantial for the field of medical research. Improved cell boundary determination can lead to more accurate diagnoses and better understanding of cell-to-cell interactions, which are critical in cancer research and the development of immunotherapies.

The use of advanced AI algorithms for cell segmentation represents a leap forward in the precision of spatial biology. This precision is essential for identifying the complex interplay of cells within the tumor microenvironment, which can influence the effectiveness of immunotherapies. By providing researchers with tools that offer comprehensive coverage and customizable options, 10x Genomics is facilitating a more targeted approach to cancer treatment research.

The long-term benefits of these advancements could be significant, potentially leading to breakthroughs in how we understand and treat cancer. However, the success of these products in the research community will hinge on their ease of integration into existing workflows and their ability to deliver on the promised accuracy and flexibility.

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries

Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types

PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.

"We built Xenium to be the best performing platform for in situ analysis, not only at launch, but for the long term," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "These new products are a testament to how we listen closely to our customers to build products that are most responsive to their needs. We have several more launches planned for Xenium this year, as we continue to innovate, enhance and expand our menu of high-performing Xenium assays to help customers answer their specific research questions."

Xenium In Situ Cell Segmentation Kit
The Xenium In Situ Cell Segmentation Kit improves the determination of cell boundaries by using a stain and algorithmic technique developed and validated through custom-trained machine learning models. Key features:

• Precise cell segmentation: Use multiple morphological features and a purpose-built algorithm for data-driven, high-confidence transcript-to-cell assignments.
• Diverse stains for comprehensive coverage: Easily capture and visualize tissue architecture in four channels from epithelial and stromal cells, to immune markers, to cell interiors and nuclei.
• State-of-the-art, custom-built algorithm: Obtain more accurate cell segmentation with an advanced AI algorithm specifically trained on real-world Xenium cellular and tissue data.
• Immediate access to data: Get interpretation-ready data as soon as the Xenium run is done in open formats that enable seamless compatibility with third-party tools.
• Seamless workflow integration and broad tissue and sample compatibility: Cover heterogeneous cell types and tissues in human and mouse samples with a single multi-tissue cocktail, without the need to switch stains for different applications or tissue types. Validated on fresh frozen and FFPE tissues.

"While Xenium launched with a robust nuclear-based segmentation approach, we've built our new solution from the ground up to improve segmentation accuracy," added Schnall-Levin. "This solution not only enables researchers to more effectively call cell types, but it also gives more confidence that transcriptomic data is attributed to the correct cell of origin for the most accurate biological interpretation."

Quan Nguyen, Group Leader at the University of Queensland, said, "We have evaluated several computational methods to enhance cell membrane segmentation across various technologies. We found that the experimental data obtained from Xenium membrane staining consistently yields the most accurate segmentation results, leading to improved downstream analysis of cell types and cell-to-cell interactions. We will use this kit in many of our coming Xenium experiments."

Xenium Immuno-Oncology Panel
The Xenium Immuno-Oncology Panel is a comprehensive solution for unraveling the dynamic interplay between tissue biology, tumor biology and immunology. The first application-focused panel on Xenium, this assay is the latest addition to a broad menu of expertly curated and customizable gene panels optimized for specific tissue types and disease states. Key features:

• Unlock intricate details of the tumor microenvironment: Get extensive detection of diverse immune cell types and states, including their migration, regulation and function, allowing for a deeper understanding of the immune landscape within the tumor microenvironment.
• Analyze a variety of cancer types: Examine a broad spectrum of cancer types and tumor biology through the identification of tumor-specific markers, oncogenes, checkpoint proteins and mechanisms of immune evasion, providing insights for the development of targeted therapy strategies.
• Customizable panels: Expand the 380-plex pre-designed panel with up to 100 additional custom genes, enabling a tailored and cost-effective assay.

The Xenium Immuno-Oncology Panel is compatible with both fresh frozen and FFPE tissues, ensuring flexibility and reliable performance across various sample types. It is available for pre-order and is expected to ship this month.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, configuration, capabilities, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-expands-xenium-menu-with-multi-modal-cell-segmentation-kit-and-immuno-oncology-gene-panel-302096366.html

SOURCE 10x Genomics, Inc

FAQ

What did 10x Genomics announce regarding the Xenium products?

10x Genomics announced the commercial availability of the Xenium Cell Segmentation Kit and the launch of the Xenium Immuno-Oncology Panel.

What is the purpose of the Xenium Cell Segmentation Kit?

The Xenium Cell Segmentation Kit improves the determination of cell boundaries using a stain and advanced AI algorithms for precise cell segmentation.

What features does the Xenium Cell Segmentation Kit offer?

The kit provides precise cell segmentation, diverse stains for comprehensive coverage, a custom-built algorithm, immediate access to data, and seamless workflow integration with broad tissue compatibility.

Who is Quan Nguyen and what did he say about the Xenium membrane staining?

Quan Nguyen, a Group Leader at the University of Queensland, mentioned that the experimental data obtained from Xenium membrane staining consistently yields the most accurate segmentation results, improving downstream analysis of cell types and interactions.

What is the Xenium Immuno-Oncology Panel designed for?

The Xenium Immuno-Oncology Panel is designed to unravel the dynamic interplay between tissue biology, tumor biology, and immunology, providing extensive detection of diverse immune cell types and states.

What are the key features of the Xenium Immuno-Oncology Panel?

The panel allows for in-depth analysis of the tumor microenvironment, examination of various cancer types, and customization with up to 100 additional custom genes for tailored assays.

How is the Xenium Immuno-Oncology Panel compatible with different tissue types?

The panel is compatible with both fresh frozen and FFPE tissues, ensuring flexibility and reliable performance across various sample types.